BR112017006240A2 - novos compostos - Google Patents
novos compostosInfo
- Publication number
- BR112017006240A2 BR112017006240A2 BR112017006240A BR112017006240A BR112017006240A2 BR 112017006240 A2 BR112017006240 A2 BR 112017006240A2 BR 112017006240 A BR112017006240 A BR 112017006240A BR 112017006240 A BR112017006240 A BR 112017006240A BR 112017006240 A2 BR112017006240 A2 BR 112017006240A2
- Authority
- BR
- Brazil
- Prior art keywords
- new compounds
- pyrazole
- salt
- compound
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417018.7A GB201417018D0 (en) | 2014-09-26 | 2014-09-26 | Novel compounds |
| PCT/EP2015/071798 WO2016046241A1 (en) | 2014-09-26 | 2015-09-22 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017006240A2 true BR112017006240A2 (pt) | 2017-12-12 |
Family
ID=51901174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017006240A BR112017006240A2 (pt) | 2014-09-26 | 2015-09-22 | novos compostos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10004724B2 (enExample) |
| EP (1) | EP3197895B1 (enExample) |
| JP (1) | JP6672276B2 (enExample) |
| KR (1) | KR20170054413A (enExample) |
| CN (1) | CN107074850A (enExample) |
| AU (1) | AU2015320874A1 (enExample) |
| BR (1) | BR112017006240A2 (enExample) |
| CA (1) | CA2962319A1 (enExample) |
| ES (1) | ES2796235T3 (enExample) |
| GB (1) | GB201417018D0 (enExample) |
| RU (1) | RU2017114352A (enExample) |
| WO (1) | WO2016046241A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| PL3538528T3 (pl) * | 2016-11-08 | 2021-05-31 | Bristol-Myers Squibb Company | Amidy pirolu jako inhibitory integryny alfa v |
| EA201991123A1 (ru) | 2016-11-08 | 2019-11-29 | ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV | |
| BR112019009245A2 (pt) | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | azol amidas e aminas como inibidores de alfav integrina |
| WO2018089353A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | 3-substituted propionic acids as alpha v integrin inhibitors |
| CA3042710A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors |
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND PROCESSES FOR USE |
| EP3760202A1 (en) | 2017-02-28 | 2021-01-06 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| IL316954A (en) | 2017-02-28 | 2025-01-01 | Morphic Therapeutic Inc | (Alpha-V)(beta-6)integrin inhibitors |
| BR112020008893A2 (pt) | 2017-11-07 | 2020-10-13 | Bristol-Myers Squibb Company | derivados de pirrolopirazina como inibidores de alfa v integrina |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| UY38352A (es) | 2018-08-29 | 2020-03-31 | Morphic Therapeutic Inc | Inhibidores de integrina alfavbeta6 |
| UY38353A (es) | 2018-08-29 | 2020-03-31 | Morphic Therapeutic Inc | Inhibición de integrina alfavbeta6 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9813769A (pt) | 1997-12-17 | 2000-10-10 | Merck & Co Inc | Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste. |
| EP1047425A4 (en) | 1997-12-17 | 2009-04-22 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
| DZ3263A1 (fr) | 1999-06-02 | 2000-12-07 | Merck & Co Inc | Antagonistes du recepteur de l'alpha v integrine |
| AU748949B2 (en) | 1999-06-23 | 2002-06-13 | Merck & Co., Inc. | Integrin receptor antagonists |
| WO2001024797A1 (en) * | 1999-10-04 | 2001-04-12 | Merck & Co., Inc. | Integrin receptor antagonists |
| CN1414966A (zh) | 1999-11-08 | 2003-04-30 | 麦克公司 | 用于制备咪唑烷酮αu蛋白拮抗剂的方法和中间体 |
| US7119098B2 (en) | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
| US7056909B2 (en) | 2000-07-26 | 2006-06-06 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| WO2002022616A2 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| EP1349548A4 (en) | 2001-01-03 | 2004-06-02 | Merck & Co Inc | METHOD AND COMPOSITIONS FOR TREATING PERIODONTOSIS |
| DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| BR0317600A (pt) | 2002-12-20 | 2005-11-29 | Pharmacia Corp | ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina |
| US7705018B2 (en) | 2007-03-23 | 2010-04-27 | Amgen Inc. | Substituted quinolines and their uses in treatment of inflammatory and related conditions |
| EP2211615A4 (en) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| GB201305668D0 (en) * | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3925959A1 (en) | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2014
- 2014-09-26 GB GBGB1417018.7A patent/GB201417018D0/en not_active Ceased
-
2015
- 2015-09-22 AU AU2015320874A patent/AU2015320874A1/en not_active Abandoned
- 2015-09-22 ES ES15767479T patent/ES2796235T3/es active Active
- 2015-09-22 EP EP15767479.7A patent/EP3197895B1/en active Active
- 2015-09-22 US US15/514,414 patent/US10004724B2/en not_active Expired - Fee Related
- 2015-09-22 CA CA2962319A patent/CA2962319A1/en active Pending
- 2015-09-22 RU RU2017114352A patent/RU2017114352A/ru unknown
- 2015-09-22 JP JP2017516386A patent/JP6672276B2/ja not_active Expired - Fee Related
- 2015-09-22 WO PCT/EP2015/071798 patent/WO2016046241A1/en not_active Ceased
- 2015-09-22 KR KR1020177007735A patent/KR20170054413A/ko not_active Withdrawn
- 2015-09-22 BR BR112017006240A patent/BR112017006240A2/pt not_active Application Discontinuation
- 2015-09-22 CN CN201580052202.3A patent/CN107074850A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017114352A (ru) | 2018-10-26 |
| EP3197895B1 (en) | 2020-03-11 |
| JP2017528506A (ja) | 2017-09-28 |
| JP6672276B2 (ja) | 2020-03-25 |
| WO2016046241A1 (en) | 2016-03-31 |
| ES2796235T3 (es) | 2020-11-26 |
| CA2962319A1 (en) | 2016-03-31 |
| CN107074850A (zh) | 2017-08-18 |
| AU2015320874A1 (en) | 2017-03-09 |
| US10004724B2 (en) | 2018-06-26 |
| US20170290818A1 (en) | 2017-10-12 |
| GB201417018D0 (en) | 2014-11-12 |
| EP3197895A1 (en) | 2017-08-02 |
| KR20170054413A (ko) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017006240A2 (pt) | novos compostos | |
| BR112017006253A2 (pt) | novos compostos | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| BR112016029333A2 (pt) | síntese de compostos de carbamoilpiridona policíclico | |
| MX387736B (es) | Derivados de fenoximetilo. | |
| TW201613911A (en) | Heterocyclic compounds and uses thereof | |
| BR112016028773A2 (pt) | processos para preparação de compostos antivirais | |
| BR112017006251A2 (pt) | novos compostos | |
| CR20160098A (es) | Polimorfo de los inhibidores de la syk | |
| BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
| CO2017000332A2 (es) | Coŵpuestos heterocíclicos como receptores huérfanos relacionados con retinoide gamma-t (ror γt) | |
| JOP20170169A1 (ar) | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو | |
| CL2015002027A1 (es) | Compuestos quimicos | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| EA201891278A1 (ru) | Гетероциклические индолы для применения при инфекции, вызванной вирусом гриппа | |
| EA201790496A1 (ru) | Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm | |
| EA201892449A1 (ru) | Конденсированные гетероциклические соединения | |
| MX387796B (es) | Compuestos de aminocarbonilcarbamato. | |
| BR112017019850A2 (pt) | ?processo melhorado para a preparação de apremilast? | |
| CL2018001067A1 (es) | Compuesto piranodipiridínico. | |
| AU2015309863A8 (en) | Azaindole derivative having AMPK-activating effect | |
| EA201691999A1 (ru) | Новые сульфониламинобензамидные соединения | |
| MX379401B (es) | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |